Skip to content
drillr.ai
Sign up

ALVOW

Alvotech

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS

$0.17
+15.06%
Ask drillr

  • Oct 28, 2026, 11:00 UTC

    Alvotech announced that it will release its financial results for the nine months and third quarter ended September 30, 2026, on November 11, 2026, after the U.S. market close.

    Source:

  • Oct 20, 2026, 08:30 UTC

    The U.S. Food and Drug Administration approved Alvotech’s new manufacturing process for SIMLANDI, which more than doubles output per batch.

    Source:

  • Oct 14, 2026, 08:30 UTC

    Alvotech and Advanz Pharma Corp. Ltd. announced that AVT29 was submitted to the EUROPEAN MEDICINES AGENCY as a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg).

    Source:

  • Oct 6, 2026, 20:30 UTC

    Alvotech and Lotte Biologics Co., Ltd. announced a long-term manufacturing partnership under which Lotte Biologics Co., Ltd. will produce drug substance for multiple Alvotech antibody biosimilar products at its Syracuse, New York facility for global supply.

    Source:

  • Oct 5, 2026, 08:00 UTC

    The FDA approved additional U.S. manufacturing capacity allowing Alvotech's SIMLANDI (AVT02) drug substance to be produced in either of its two Reykjavik drug substance suites.

    Source:

  • Sep 18, 2026, 09:43 UTC

    Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.

    Source:

  • Sep 16, 2026, 12:28 UTC

    Alvotech shares rose 5.58% to $5.30 in after-hours trading on September 16, 2026, ahead of an FDA review decision.

    Source:

  • Aug 21, 2026, 13:00 UTC

    Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for its proposed biosimilars AVT34 (durvalumab) and AVT87 (emicizumab) in the U.S. and selected Asian markets.

    Source:

  • Aug 19, 2026, 20:30 UTC

    Alvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.

    Source:

  • Jul 29, 2026, 13:25 UTC

    Alvotech announced that the FDA closed its inspection of its manufacturing facility in Reykjavik, Iceland, with a Voluntary Action Indicated classification.

    Source:

  • Jul 1, 2026, 08:00 UTC

    Alvotech secured a $75 million term loan facility by amending its existing credit agreement with GoldenTree Asset Management LP and other lenders.

    Source:

  • Jun 16, 2026, 03:50 UTC

    Alvotech priced a public offering of 22,666,667 ordinary shares at $3.75 per share, raising $152 million.

    Source:

  • Jun 8, 2026, 08:00 UTC

    Alvotech announced that the FDA accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio.

    Source:

  • Jun 5, 2026, 18:35 UTC

    Alvotech resubmitted Biologics License Applications (BLAs) to the FDA for its biosimilar candidates AVT05 and AVT06.

    Source: